Ganciclovir and valganciclovir are first choice drugs for the prevention and treatment of
cytomegalovirus infection and disease in solid organ and stem cell transplant recipients …

Valganciclovir and ganciclovir are widely used for the prevention of cytomegalovirus (CMV)
infection in solid organ transplant recipients, with a major impact on patients' morbidity and …

Abstract Background Valganciclovir (Valcyte/sR) has recently been approved for the
prevention of cytomegalovirus (CMV) disease in high-risk (CMV donor positive [D+ …

Background. A randomized, double-blind study was conducted to evaluate the
pharmacokinetics of ganciclovir following oral administration of ganciclovir or valganciclovir …

Introduction: Cytomegalovirus (CMV) is an opportunistic infectious complication that can
occur after allogeneic hematopoietic cell transplantation (HCT). The mainstay of treatment …

Valganciclovir (VGC) is an oral prodrug of ganciclovir (GCV) recently introduced for
prophylaxis and treatment of cytomegalovirus infection. Optimal concentration exposure for …

Background Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …

Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or
treat cytomegalovirus infection in solid-organ transplant recipients. The valganciclovir …

Background. A 3-month course of prophylaxis is usually recommended for cytomegalovirus
(CMV) D+/R− renal transplant recipients. Based on recent data, up to 6 months of …

ABSTRACT A population pharmacokinetics analysis was performed after intravenous
ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus …